In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 4, 2008, Pages 1545-1548

  Desbois, Delphine ^a   Roquebert, Bénédicte ^a   Peytavin, Gilles ^a   Damond, Florence ^a   Collin, Gilles ^a   Bénard, Antoine ^c   Campa, Pauline ^b   Matheron, Sophie ^a   Chêne, Geneviève ^c   Brun Vézinet, Françoise ^a   Descamps, Diane ^a  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; SAQUINAVIR; TIPRANAVIR;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION;

HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-2; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PYRIMIDINONES; SAQUINAVIR; SULFONAMIDES;

EID: 42049104340     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01284-07     Document Type: Article

References (17)

1. + cell counts and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 17:S49-S54.
2. Colson, P., M. Henry, M. Tivoli, H. Gallais, J. A. Gastaut, J. Moreau, and C. Tamalet. 2003. Polymorphism and drug-selected mutations in the reverse transcriptase of HIV-2 from patients living in southern France, abstr. 145. XII Int. HIV Drug Resist. Workshop: Basic Princ. Clin. Implications, Los Cabos, Mexico.
3. Damond, F., F. Brun-Vezinet, S. Matheron, G. Peytavin, P. Campa, S. Pueyo, F. Mammano, S. Lastere, I. Farfara, F. Simon, G. Chene, and D. Descamps. 2005. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J. Clin. Microbiol. 43:484-487.
4. Damond, F., G. Collin, S. Matheron, G. Peytavin, P. Campa, S. Delarue, A. Taieb, A. Benard, G. Chene, F. Brun-Vezinet, and D. Descamps. 2005. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene. Antivir. Ther. 10:861-865. (Letter.)
5. De Wit, M., I. Keuleers, E. Gustin, I. Dierynck, S. Hallenberger, and K. Hertogs. 2007. Binding kinetics of PI to wild type and multi drug resistant HIV-1 proteases: a mechanistic study of the genetic barrier to resistance to darunavir, abstr. 605. XIV Conf. Retroviruses Opportunistic Infect., Los Angeles, CA, 25 to 28 February 2007.
6. Koh, Y., H. Nakata, K. Maeda, H. Ogata, G. Bilcer, T. Devasamudram, J. F. Kincaid, P. Boross, Y. F. Wang, Y. Tie, P. Volarath, L. Gaddis, R. W. Harrison, I. T. Weber, A. K. Ghosh, and H. Mitsuya. 2003. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47:3123-3129.
7. Kovalevsky, A. Y., F. Liu, S. Leshchenko, A. K. Ghosh, J. M. Louis, R. W. Harrison, and I. T. Weber. 2006. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J. Mol. Biol. 363:161-173.
8. Matheron, S., F. Damond, A. Benard, A. Taieb, P. Campa, G. Peytavin, S. Pueyo, F. Brun-Vezinet, and G. Chene. 2006. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 20:459-462.
9. Ntemgwa, M., B. G. Brenner, M. Oliveira, D. Moisi, and M. A. Weinberg. 2007. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents Chemother. 51:604-610.
10. Parreira, R., F. Monteiro, E. Padua, J. Piedade, T. Venenno, M. T. Paixao, and A. Esteves. 2006. Natural polymorphisms of HIV type 2 pol sequences from drug-naive individuals. AIDS Res. Hum. Retroviruses 22:1178-1182.
11. Pieniazek, D., M. Rayfield, D. J. Hu, J. N. Nkengasong, V. Soriano, W. Heneine, C. Zeh, S. M. Agwale, C. Wambebe, L. Odama, and S. Z. Wiktor. 2004. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 18:495-502.
12. Ren, J., L. E. Bird, P. P. Chamberlain, G. B. Stewart-Jones, D. I. Stuart, and D. K. Stammers. 2002. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA 99:14410-14415.
13. Rodés, B., A. Holguín, V. Soriano, M. Dourana, K. Mansinho, F. Antunes, and J. González-Lahoz. 2000. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J. Clin. Microbiol. 38:1370-1374.
14. Rodés, B., J. Sheldon, C. Toro, V. Jimenez, M. A. Alvarez, and V. Soriano. 2006. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J. Antimicrob. Chemother. 57:709-713.
15. van der Ende, M. E., K. Brinkman, M. Keuters, J. M. Prins, S. A. Danner, A. D. M. E. Osterhaus, and M. Schutten. 2000. Antiretroviral therapy in HIV2 infected patients in the Netherlands: results in 17 patients. AIDS 14:S104.
16. Witvrouw, M., C. Pannecouque, W. M. Switzer, T. M. Folks, E. De Clercq, and W. Heneine. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9:57-65.
17. Yeni, P. 2006. Rapport 2006: prise en charge médicale des personnes infectées par le VIH. Flammarion, Paris, France.